Background: Colorectal cancer is a frequent disease in Norway. New and improved surgical techniques and the implementation of adjuvant and neoadjuvant therapy have improved 5-year survival rates significantly. Accurate preoperative assessment of tumour extent is essential for choosing the appropriate therapeutic strategy, and thus for patient prognosis. Both established and recent imaging methods are presented and discussed.
Material And Methods: This review is based on a selection of articles from Pub-Med, with an emphasis on meta-analyses and prospective investigations, and on the clinical experiences of the authors.
Results And Interpretation: Recto-/colonoscopy with biopsy is still the most common approach for diagnosis. In Norway, magnetic resonance imaging (MRI) is the preferred imaging modality for rectal cancer. With optimal technique MRI provides a good visualisation of important local prognostic factors. Endoscopic ultrasound is the modality of choice for small, superficial tumours. The role of multidetector computer tomography (MDCT) in the local evaluation of rectal cancer is not entirely established. The evaluation of metastases of regional lymph nodes is a challenge with all the available imaging modalities. CT-colonography is a recent method for imaging of the colon. It provides an accurate evaluation of the bowel, of tumour invasion outside the bowel wall and of extracolonic (glandula- and liver-) metastases. Double-contrast barium enema, or abdominal and pelvic CT are alternative methods for evaluation of colon cancer. CT of the thorax and abdomen is recommended for screening of distant metastasis.
Download full-text PDF |
Source |
---|
Aims: With the recently validated tool for estimating chronic pain after colorectal cancer surgery, the aims of this study were to calculate the prevalence and to identify predictive risk factors for chronic pain after colorectal cancer treatment.
Method: Clinical data from colorectal cancer patients treated between 2001 and 2014 were obtained from the Danish Colorectal Cancer Group database. In 2016, all survivors were invited to participate in a national cross-sectional questionnaire study on long-term functional outcomes, including the chronic pain questionnaire.
Clin Transl Radiat Oncol
March 2025
University Medical Center Utrecht, Department of Radiation Oncology, Utrecht, the Netherlands.
Background And Purpose: This study assessed the treatment time of online adaptive (i.e. Adapt-to-Shape, ATS) and virtual couch shift (i.
View Article and Find Full Text PDFAME Case Rep
October 2024
Department of Oncology, Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University, Wenzhou, China.
Background: Hyperammonemic encephalopathy caused by high-dose infusion of 5-fluorouracil (5-FU) is a rare adverse reaction in rectal cancer patients with an incidence rate of 5.7%. Although the patient could be restored to normal after supportive treatments, the occurrence of this side effect was still inevitable.
View Article and Find Full Text PDFAME Case Rep
November 2024
Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Background: Mucinous adenocarcinoma is a rare type of colorectal cancer (CRC) associated with poor prognosis, particularly when it includes signet ring cell components. Furthermore, its rate of microsatellite instability-high (MSI-H) is significantly higher compared to non-mucinous adenocarcinoma. Immunotherapy has emerged as the standard treatment for MSI-H metastatic CRC (mCRC).
View Article and Find Full Text PDFFEBS Open Bio
January 2025
Clinical Measurement Sciences, Global Research & Development, EMD Serono, Billerica, MA, USA.
MAPK signaling activation is an important driver event in colorectal cancer (CRC) tumorigenesis that informs therapy selection, but detection by liquid biopsy can be challenging. We analyze real-world comprehensive genomic profiling (CGP) data to explore the landscape of alterations in BRAF or RAS in CRC patients (N = 51 982) and co-occurrence with other biomarkers. A pathogenic RAS or BRAF alteration was found in 63.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!